Strong Antigen-specific T-cell Immunity Induced by a Recombinant Human TERT Measles Virus Vaccine and Amplified by a DNA/viral Vector Prime Boost in IFNAR/CD46 Mice

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2019 Jan 19

PMID 30656384

Citations 1

Authors

Elodie Pliquet

Claude Ruffie

Marie Escande

Jessie Thalmensi

Valerie Najburg

Chantal Combredet

Thomas Bestetti

Marion Julithe

Christelle Liard

Thierry Huet

Simon Wain-Hobson

Frederic Tangy

Pierre Langlade-Demoyen

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy is seeing an increasing focus on vaccination with tumor-associated antigens (TAAs). Human telomerase (hTERT) is a TAA expressed by most tumors to overcome telomere shortening. Tolerance to hTERT can be easily broken both naturally and experimentally and hTERT DNA vaccine candidates have been introduced in clinical trials. DNA prime/boost strategies have been widely developed to immunize efficiently against infectious diseases. We explored the use of a recombinant measles virus (MV) hTERT vector to boost DNA priming as recombinant live attenuated measles virus has an impressive safety and efficacy record. Here, we show that a MV-TERT vector can rapidly and strongly boost DNA hTERT priming in MV susceptible IFNAR/CD46 mouse models. The cellular immune responses were Th1 polarized. No humoral responses were elicited. The 4 kb hTERT transgene did not impact MV replication or induction of cell-mediated responses. These findings validate the MV-TERT vector to boost cell-mediated responses following DNA priming in humans.

Citing Articles

Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.

Ebenig A, Lange M, Muhlebach M NPJ Vaccines. 2022; 7(1):119.

PMID: 36243743 PMC: 9568972. DOI: 10.1038/s41541-022-00543-4.

References

Brandler S, Tangy F . Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis. 2007; 31(2-3):271-91. DOI: 10.1016/j.cimid.2007.07.012. View

Bluestone J, Small E . The future of cancer treatment: will it include immunotherapy?. Cancer Cell. 2012; 22(1):7-8. DOI: 10.1016/j.ccr.2012.06.009. View

Lu S . Heterologous prime-boost vaccination. Curr Opin Immunol. 2009; 21(3):346-51. PMC: 3743086. DOI: 10.1016/j.coi.2009.05.016. View

Lu M, Deng J, Cao Y, Fang D, Zhang Y, Yang S . Prognostic role of telomerase activity in gastric adenocarcinoma: A meta-analysis. Exp Ther Med. 2012; 3(4):728-734. PMC: 3438691. DOI: 10.3892/etm.2012.471. View

Pascolo S, Bervas N, Ure J, Smith A, Lemonnier F, Perarnau B . HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 1997; 185(12):2043-51. PMC: 2196346. DOI: 10.1084/jem.185.12.2043. View

Karanikas V, Zamanakou M, Soukou F, Kerenidi T, Gourgoulianis K, Germenis A . Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer. Immunol Cell Biol. 2010; 88(5):575-85. DOI: 10.1038/icb.2010.8. View

Low K, Tergaonkar V . Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci. 2013; 38(9):426-34. DOI: 10.1016/j.tibs.2013.07.001. View

Guillerme J, Gregoire M, Tangy F, Fonteneau J . Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology (Basel). 2014; 2(2):587-602. PMC: 3960896. DOI: 10.3390/biology2020587. View

Durward M, Harms J, Splitter G . Antigen specific killing assay using CFSE labeled target cells. J Vis Exp. 2010; (45). PMC: 3159590. DOI: 10.3791/2250. View

10.

Draper S, Heeney J . Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2009; 8(1):62-73. DOI: 10.1038/nrmicro2240. View

11.

Hallengard D, Lum F, Kummerer B, Lulla A, Lulla V, Garcia-Arriaza J . Prime-boost immunization strategies against Chikungunya virus. J Virol. 2014; 88(22):13333-43. PMC: 4249109. DOI: 10.1128/JVI.01926-14. View

12.

Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak R, Thomas S . Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015; 15(5):519-27. DOI: 10.1016/S1473-3099(15)70043-5. View

13.

Bachmair A, Finley D, Varshavsky A . In vivo half-life of a protein is a function of its amino-terminal residue. Science. 1986; 234(4773):179-86. DOI: 10.1126/science.3018930. View

14.

Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B . A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol. 2003; 77(21):11546-54. PMC: 229349. DOI: 10.1128/jvi.77.21.11546-11554.2003. View

15.

Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C . Rescue of measles viruses from cloned DNA. EMBO J. 1995; 14(23):5773-84. PMC: 394696. DOI: 10.1002/j.1460-2075.1995.tb00266.x. View

16.

Zanetti M . A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol. 2016; 14(2):115-128. DOI: 10.1038/nrclinonc.2016.67. View

17.

Moss W, Griffin D . Measles. Lancet. 2011; 379(9811):153-64. DOI: 10.1016/S0140-6736(10)62352-5. View

18.

Komarova A, Combredet C, Meyniel-Schicklin L, Chapelle M, Caignard G, Camadro J . Proteomic analysis of virus-host interactions in an infectious context using recombinant viruses. Mol Cell Proteomics. 2011; 10(12):M110.007443. PMC: 3237069. DOI: 10.1074/mcp.M110.007443. View

19.

Shay J, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33(5):787-91. DOI: 10.1016/S0959-8049(97)00062-2. View

20.

Eggermont A, Kroemer G, Zitvogel L . Immunotherapy and the concept of a clinical cure. Eur J Cancer. 2013; 49(14):2965-7. DOI: 10.1016/j.ejca.2013.06.019. View